Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
Date:2/21/2012

PITTSBURGH, Feb. 21, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months and year ended December 31, 2011.

Financial Results

  • Adjusted diluted EPS of $0.53 for the three months ended December 31, 2011 compared to $0.45 for the same prior year period, an increase of 18%;

  • Adjusted diluted EPS of $2.04 for the year ended December 31, 2011 compared to $1.61 for the prior year, an increase of 27%;

  • Total revenues of $1.53 billion for the three months ended December 31, 2011 compared to $1.43 billion for the same prior year period, an increase of 7%; Fourth quarter revenues were negatively impacted by foreign currency translation, as discussed further below.  The impact was 1% (approximately $18M) compared to the same prior year period, and 2.5% (approximately $39M) on a sequential quarter basis;

  • Total revenues of $6.13 billion for the year ended December 31, 2011 compared to $5.45 billion for the prior year, an increase of 12%;  

  • On a GAAP basis, diluted EPS of $0.30 for three months ended December 31, 2011 compared to $0.01 for the same prior year period;

  • On a GAAP basis, diluted EPS of $1.22 for the year ended December 31, 2011 compared to $0.68 for the prior year, an increase of 79%;

  • Adjusted cash provided by operating activities of $882 million for the year ended December 31, 2011 compared to $781 million for the prior year;

  • On a GAAP basis, cash flow from operating activities of $720 million for the year ended December 31, 2011 compared to $931 million for the prior year.

  • Heather Bresch, Mylan's Chief Executive Officer stated: "Our excellent financial results once again demonstrate our ability to deliver significant growth while continuing to manage the inherent challenges of our industry, as well
    '/>"/>

    SOURCE Mylan Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
    2. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
    3. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
    4. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
    5. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
    6. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
    7. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
    8. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
    9. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
    10. Mylan Launches First Generic Version of Teveten® Tablets
    11. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
    (Date:8/28/2015)...  IP Shakti, LLC, today announced that it has changed ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... identity signifies our transformation into a company focused on patent ... patent claim validity." ... Shield™ platform, the Company commenced a corporate re-branding initiative in ...
    (Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
    Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
    ... OMER ) today announced that it has obtained ... California to a new series of antifibrinolytic agents. These optimized ... surgical and traumatic bleeding. "This is a ... for patients. With the withdrawal of Trasylol® from the market ...
    ... Jan. 5, 2011 Karyopharm Therapeutics Inc., a pioneer ... modulators, announces the recruitment of a highly experienced cancer ... Chief Executive Officer. Dr. Kauffman will join Sharon Shacham, ... and Development, as its executive management team. Kauffman,s appointment ...
    Cached Medicine Technology:Omeros Licenses Novel Antifibrinolytic Agents 2Omeros Licenses Novel Antifibrinolytic Agents 3Omeros Licenses Novel Antifibrinolytic Agents 4Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 2Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 3
    (Date:8/30/2015)... ... ... Lizzie’s Lice Pickers , a company that offers professional live removal ... lice head checks for just $10, which is a significant discount from the normal ... lice treatment products. “With kids returning to school, it is very important to be ...
    (Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and ... and skin care experience having spent the last 25 years working in operations, ...
    (Date:8/29/2015)... ... August 30, 2015 , ... ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The ... simple digital handwritten signature. , Clinical trial sites can now use ...
    (Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and ... is to increase acceptance of the chiropractic field in the military. All too often ... Although Chiropractic was made available to the VA program over a decade ago, ...
    (Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
    Breaking Medicine News(10 mins):Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
    ... be removed ahead of time, FDA says, , , THURSDAY, ... Drug Administration warned Thursday that some medication skin patches ... MRI. , Thursday,s warning applies to brand name and ... and pain-control patches. , Some of these patches do ...
    ... How messages sent within stem cells through a specific communication ... cells in humans, has been discovered by scientists of the ... to be published in the March 6 issue of ... demonstrated the importance of the pathway, known as the noncanonical ...
    ... New Rochelle, NY, March 5, 2009Serious flaws in a ... C reduce the effectiveness of chemotherapeutic drugs in the ... of Alternative and Complementary Therapies , a journal ... This report is available free online at ...
    ... potential risk from exposure to medications, chemicals and other ... risks of taking cold medication or using certain cleaning ... the phone. A new Web site ( ... finding the latest information about the potential risks of ...
    ... therapies to restore sight, experts suggest , , THURSDAY, March ... major role in two forms of childhood blindness has ... The discovery of the link between the retinal gene ... is important because it pinpoints a new retinal metabolic ...
    ... top 100 property and casualty insurers closed 2008 with ... years, while the top 100 life insurers suffered unprecedented ... Data 2008 Top 100 Performance Monitor revealed a 67.7 ... the industry,s top property and casualty insurers, from $48.8 ...
    Cached Medicine News:Health News:Skin Patches Can Cause Burns During MRIs 2Health News:Support for adjunctive vitamin C treatment in cancer 2Health News:New Online Service Helps Expectant Moms 2Health News:Retinal Gene Is Linked to Childhood Blindness 2Health News:Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008 2Health News:Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008 3
    ... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
    Calcitonin RIA Kit...
    ... The Matrix Perimeter utilizes Welch ... a significant breakthrough in visual field ... capabilities, tools to characterize glaucoma and ... Humphrey FDT Perimeter, the Matrix doubles ...
    ... digital camera system by KARL STORZ, a ... camera systems. Digital Source Sampling technology, applied ... fully digital transfer of information with no ... as well as loss-free data storage on ...
    Medicine Products: